These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 32315234)
41. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Saborowski A; Vogel A; Segatto O Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108 [TBL] [Abstract][Full Text] [Related]
42. Raw Fish Consuming Behavior Related to Liver Fluke Infection among Populations at Risk of Cholangiocarcinoma in Nakhon Ratchasima Province, Thailand. Chavengkun W; Kompor P; Norkaew J; Kujapun J; Pothipim M; Ponphimai S; Kaewpitoon SJ; Padchasuwan N; Kaewpitoon N Asian Pac J Cancer Prev; 2016; 17(6):2761-5. PubMed ID: 27356687 [TBL] [Abstract][Full Text] [Related]
43. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. Li F; Peiris MN; Donoghue DJ Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106 [TBL] [Abstract][Full Text] [Related]
45. Chimeric transcripts observed in non-canonical FGFR2 fusions with partner genes' breakpoint located in intergenic region in intrahepatic cholangiocarcinoma. Yin L; Han Z; Feng M; Wang J; Xie Z; Yu W; Fu X; Shen N; Wang X; Duan A; Zhang Y; Ma J Cancer Genet; 2022 Aug; 266-267():39-43. PubMed ID: 35749865 [TBL] [Abstract][Full Text] [Related]
46. Behavior-related risk factors for opisthorchiasis-associated cholangiocarcinoma among rural people living along the mekong river in five greater mekong subregion countries. Songserm N; Charoenbut P; Bureelerd O; Pintakham K; Woradet S; Vanhnivongkham P; Cua LN; Uyen NTT; Cuu NC; Sripa B Acta Trop; 2020 Jan; 201():105221. PubMed ID: 31654901 [TBL] [Abstract][Full Text] [Related]
47. Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma. Wang J; Shi Y; Chen J; Liu J; Zhao X; Pang J; Sun X; Tian Y; Ou Q; Xia F; Chen Y Cancer Biol Ther; 2023 Dec; 24(1):2223375. PubMed ID: 37337460 [TBL] [Abstract][Full Text] [Related]
48. Changing patterns of prevalence in Opisthorchis viverrini sensu lato infection in children and adolescents in northeast Thailand. Khuntikeo N; Sithithaworn P; Loilom W; Namwat N; Yongvanit P; Thinkhamrop B; Kiatsopit N; Andrews RH; Petney TN Acta Trop; 2016 Dec; 164():469-472. PubMed ID: 27794488 [TBL] [Abstract][Full Text] [Related]
49. Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangiocarcinoma. Akai PS; Pungpak S; Chaicumpa W; Viroj K; Bunnag D; Befus AD Trans R Soc Trop Med Hyg; 1994; 88(4):471-4. PubMed ID: 7570848 [TBL] [Abstract][Full Text] [Related]
50. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Chusorn P; Namwat N; Loilome W; Techasen A; Pairojkul C; Khuntikeo N; Dechakhamphu A; Talabnin C; Chan-On W; Ong CK; Teh BT; Yongvanit P Tumour Biol; 2013 Jun; 34(3):1579-88. PubMed ID: 23417858 [TBL] [Abstract][Full Text] [Related]
51. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Chong DQ; Zhu AX Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149 [TBL] [Abstract][Full Text] [Related]
52. Spatial analysis of hepatobiliary abnormalities in a population at high-risk of cholangiocarcinoma in Thailand. Thinkhamrop K; Suwannatrai AT; Chamadol N; Khuntikeo N; Thinkhamrop B; Sarakarn P; Gray DJ; Wangdi K; Clements ACA; Kelly M Sci Rep; 2020 Oct; 10(1):16855. PubMed ID: 33033306 [TBL] [Abstract][Full Text] [Related]
53. Factors Associated with Periductal Fibrosis Diagnosed by Ultrasonography Screening among a High Risk Population for Cholangiocarcinoma in Northeast Thailand. Intajarurnsan S; Khuntikeo N; Chamadol N; Thinkhamrop B; Promthet S Asian Pac J Cancer Prev; 2016; 17(8):4131-6. PubMed ID: 27644673 [TBL] [Abstract][Full Text] [Related]
54. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Sriamporn S; Pisani P; Pipitgool V; Suwanrungruang K; Kamsa-ard S; Parkin DM Trop Med Int Health; 2004 May; 9(5):588-94. PubMed ID: 15117303 [TBL] [Abstract][Full Text] [Related]
55. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma. Ang C J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238 [TBL] [Abstract][Full Text] [Related]
56. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. King G; Javle M Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915 [TBL] [Abstract][Full Text] [Related]
60. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas. Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]